DOCSLIB.ORG

(10) Patent No.: US 8,512,759 B1 Mcmahen Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(10) Patent No.: US 8,512,759 B1 Mcmahen Et Al US008512759B1 (12) United States Patent (10) Patent No.: US 8,512,759 B1 McMahen et al. (45) Date of Patent: Aug. 20, 2013 (54) METHODS OF FORMULATING AND 4,996,047 A 2f1991 Kelleher DESIGNING LIOUID DRUG SUSPENSIONS A E. E.Ca et al. CONTAINING ON EXCHANGE RESN 2003/OO99711 A1 5/2003 Meadows et al. PARTICLES 2004/0052849 A1 3, 2004 Ohare 2005/0013792 A1 1/2005 Hollenbeck et al. ......... 424/78.1 (75) Inventors: Russell McMahen, Flower Mound, TX 2006/0193877 A1 8/2006 Tengler et al. (US); Mark Tengler, Colleyville, TX 2007/0059.270 A1 3, 2007 Hall et al. s s 2007. O140983 A1 6/2007 Hall et al. (US); Michael Sloane, Forth Worth, TX 2007. O148239 A1 6, 2007 Hall et al. (US); Daniel Lockhart, Euless, TX (US) 2009 OO11027 A1 1/2009 Pathak et al. 2009,0176884 A1 7/2009 Dickerson et al. (73) Assignee: Neos Therapeutics, LP, Grand Prairie, TX (US) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Prabhu et al. (“Comparison of Dissolution Profiles for Sustained patent is extended or adjusted under 35 Release Resinates of BCS Class I Drugs Using USP Apparatus 2 and U.S.C. 154(b) by 0 days. shiel Note”, AAPS PharmSciTech, vol. 9, No. 3, Sep. (21) Appl. No.: 13/490,697 Hadzija et al. (Journal of Forensic Sciences 1996; 41(5):878-880).* Prabhu et al., “Comparison of Dissolution Profiles for Sustained (22) Filed: Jun. 7, 2012 Release Resinates of BCS Class 1 Drugs. Using USP Apparatus 2 and 9 4: A Technical Note”, AAPS PharmSciTech, vol. 9, No.3, Sep. 2008. Related U.S. Application Data FDA's "Guidance for industry” (Jun. 14, 2006, pp. 1-35). (62) Division of application No. 12/985,340, filed on Jan.5, * cited by examiner 2011. (60) Provisional application No. 61/292.420, filed on Jan. Primary Examiner — Aradhana Sasan 5, 2010. (74) Attorney, Agent, or Firm — Hunton & Williams LLP (51) Int. Cl. A 6LX 9/50 (2006.01) (57) ABSTRACT A6 IK 9/14 (2006.01) The invention relates to the formulation and quality control of A6 IK3I/74 (2006.01) liquid drug Suspensions. In particular, the invention relates to (52) U.S. Cl. methods of formulatinggl1C liquid Suspensionsp comprisingpr1S1ng drug USPC ........................... 424/501; 424/78.1; 424/486 containing resin particles. The invention also relates to meth (58) Field of Classification Search ods of confirming the acceptability of drug-containing resin USPC ......................................... 424/78.1, 486,501 particles for use in formulating liquid drug Suspensions. The See application file for complete search history. invention further relates to methods of formulating liquid Suspensions in which drug-containing resin particles, the liq (56) References Cited uid Suspension, or both are modified to achieve a desired in vitro dissolution profile. The invention also relates to a novel U.S. PATENT DOCUMENTS dissolution method and methods of predicting in vivo 2.990,332 A 6/1961 Keating bioeduivalence based on in vitro dissolution methods. 4,221,778 A 9/1980 Raghunathan 4,619,934 A 10, 1986 Sunshine et al. 4,762,709 A * 8/1988 Sheumaker ................ 424/78.11 18 Claims, 14 Drawing Sheets Brand Tussionex sea-a-a-a-row. so xxxxxxxxxxxxxx:xxxxxxxxxxx: ---4- ParticleSize (m) U.S. Patent Aug. 20, 2013 Sheet 1 of 14 US 8,512,759 B1 () \ ?onpoldIeul ?IJOueduol?n|OSSIC] U.S. Patent Aug. 20, 2013 Sheet 2 of 14 US 8,512,759 B1 ~——————~~~~ uo?eued?ja U.S. Patent Aug. 20, 2013 Sheet 3 of 14 US 8,512,759 B1 SÐÅ|OJHAUI….….…….……….….….……….……….…….……….….….……….…….….……….…….….….….….….………:() 9ER|[15)||-|| oN,· ******************************************************************************************************************************************e—eneuquinba.…….….……….………….………….….….……uo?ejed?ja?ae?…….….……….…|?onpolaeloquea (¿eqe?deope) |. (),K??oeds-øs. ?š??šišmiš|°||paleooºpepeoTleul-!-|}?ºlºE.Kessvuonnossid |-· O?uoiellSºulse!!! ubuens||No.ººººº,) 9^?10\/?u U.S. Patent Aug. 20, 2013 Sheet 4 of 14 US 8,512,759 B1 Effect of pH Release 1OO 90 8O 7O 6O 5O 40 3O - A - Chlorpheniramine (at 90 min) 2O -- Hydrocodone (at 90 min) 1O O 3.O 3.5 4.O 4.5 5. O 5.5 6.O 6.5 pH Figure 4 Dissolution Performed in 0.1N HCl (pH - 1.2) 100 90 80 70 60 50 40 - A - Chlorpheniramine 30 20 10O --A A A O 2 4 6 8 10 12 14 Time (Hours) Figure 5 U.S. Patent Aug. 20, 2013 Sheet 5 of 14 US 8,512,759 B1 Chlorpheniramine Plasma Level 1 2 1 O 8 6 4 O O 5 1 O 15 2O 25 Time (Hours) Figure 6 Hydrolone Dissolution Profile -- Low Coating Level -O- Medium Coating Level -3- High Coating Level Figure 7 U.S. Patent Aug. 20, 2013 Sheet 6 of 14 US 8,512,759 B1 Hvdrocodone In-Vitro Dissolution Profile 100 90 80 70 IC 60 : 50 SS 40 e 30 -0 Lower Coating Level 20 -O-Reference Listed Drug O - A Higher Coating Level O O 2 4. 6 8 O Time (hours) Figure 8 Hydrocodone Release Rates 120 80 t vs CD 60 --8=E, 5:S 40 -O-Test A -OH Test B 20 - A-TuSSionex Brand O O 2 4 6 8 10 Time (Hours) Figure 9 U.S. Patent Aug. 20, 2013 Sheet 7 of 14 US 8,512,759 B1 Chlorpheniramine Release Rates 100 80 60 -O-Test A 40 1. -H Test B SS 20 - A - TuSSionex Brand O O 2 4 6 8 10 -20 Time (Hours) Figure 10 7 - s s 3. X l m - TIME HOURS) ESA, "ESE REFERENCE Figure 11 U.S. Patent Aug. 20, 2013 Sheet 8 of 14 US 8,512,759 B1 9 8 a 6 5 4 " a. D == REFERENCE Figure 12 7O 60 y 3E-07e9187x 50 2 R = O.9877 40 1O O 8O 85 90 95 1OO 105 Amount Dissolved Figure 13 U.S. Patent Aug. 20, 2013 Sheet 9 of 14 US 8,512,759 B1 Calculated Hydrocodone Plasma profile in Test B 16 14 12 2 - A - Calculated Profile 3 10 -o-Clinical Data 8 S 6 4 2 O & O 5 10 15 20 25 Time (Hours) Figure 14 Hydrocodone Polistirex Resin High Coating Level - Lab Batch 450 400 350 3O.O | gld 25.0 t; 20.0 -o-Day 0 | 150 -K)- Day 7 | - A Day 14 10.0 -O-Day 30 50 O.O O 1 2 3 4 5 6 7 8 9 Time (Hours) Figure 15 U.S. Patent Aug. 20, 2013 Sheet 10 of 14 US 8,512,759 B1 Hydrocodone Polistirex Resin Low Coating Level - Lab Batch 95.0 90.0 850 80.0 75.0 70.0 265.0 Š600 55.0 500 450 40.0 O 1 2 3 4 5 6 7 8 9 Time (Hours) Figure 16 Hvdrocodone Release Profile - Pilot Batch 60 50 40 S. 30 A1 SS -A-Day 1 20 -O-Day 28 10 O O 2 4 6 8 10 12 14 Time (Hours) Figure 17 U.S. Patent Aug. 20, 2013 Sheet 11 of 14 US 8,512,759 B1 Hydrocodone Release Profile Final Mix at 50°C OOO 90.0 t 80.0 3. s 70.0 -(-DaVay O -O-Day 14 600 -x-Day 30 50.0 O 2 3 4 5 6 7 8 9 Time (Hours) Figure 18 Hydrocodone Release Profile Sample with pH of 3.78 80.0 70.0 ux-*-3– t 60.0 50.0 e 40.0 -H Initial A4 & 30.0 0-7 Day. -O- 14 Day 20.0 -X-21 Day 10.0 O.O O 2 3 4 5 6 7 8 9 Time (Hours) Figure 19 U.S. Patent Aug. 20, 2013 Sheet 12 of 14 US 8,512,759 B1 Hydrocodone Release Profile Sample without Chlorpheniramine Polistirex 7O.O 6O.O 50.0 s 40.0 -HDay 1 SY 30.0 1. -O-Day 7 2O.O - A - 4 Weeks -O-3 Months O.O O O 2 3 4 5 6 7 8 9 Time (Hours) Figure 20 Low Coated Hydrocodone Polistirex 1OO 90 8O 7O 5 6.O 3 50 - RaW Material 40 -o-Suspension - Day 1 or 30 2O O O 2 4 6 8 1O Time (Hours) Figure 21 U.S. Patent Aug. 20, 2013 Sheet 13 of 14 US 8,512,759 B1 High Coated Hydrocodone Polistirex 2 5 -- RaW Material -o-Suspension - Day 1 O O 2 4 6 8 1O Time (Hours) Figure 22 2 i : Brand Tussionex sea----------- ; : :*::::::::::: & xxxx:x:x:i:ii:3:::::::::::::::::::::::::::::::4- x: : . O , Particle Size Crn) Figure 23 U.S. Patent Aug. 20, 2013 Sheet 14 of 14 US 8,512,759 B1 arts: Sigis is gig ressessessex. O Particle Size (in -Greater than 18Oum - Average -15Dum to 173um - Average - DSurn to 24 um - Average -75um to 105um - Average -Pan Sample - Average -125um to 49 unn - kerage Figure 24 US 8,512,759 B1 1. 2 METHODS OF FORMULATING AND a carrier resin Such as an ion-exchange resin. However, while DESIGNING LIOUID DRUG SUSPENSIONS complexing drugs on ion-exchange resins has been effective CONTAINING ON EXCHANGE RESIN for taste-masking, such uncoated complexes provide only a PARTICLES relatively short delay of drug release and a poor control of drug release, because control of release rate is limited to CROSS-REFERENCE TO RELATED variation in particle size and cross-linkage of the Sulfonic APPLICATIONS acid-type resin used to prepare the adsorption compounds. Another approach to prepare liquid Suspensions having This application is a divisional application of U.S. appli Sustained-released capabilities is by coating drug resins with cation Ser.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Rediscovery of Fexinidazole
    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Effects of the Antitussive Drug Cloperastine on Ventricular Repolarization in Halothane-Anesthetized Guinea Pigs
    J Pharmacol Sci 120, 000 – 000 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Full Paper Effects of the Antitussive Drug Cloperastine on Ventricular Repolarization in Halothane-Anesthetized Guinea Pigs Akira Takahara1,*, Kaori Fujiwara1, Atsushi Ohtsuki2, Takayuki Oka2, Iyuki Namekata2, and Hikaru Tanaka2 1Department of Pharmacology and Therapeutics, 2Department of Pharmacology, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Chiba 274-8510, Japan Received May 13, 2012; Accepted August 29, 2012 Abstract. Cloperastine is an antitussive drug, which can be received as an over-the-counter cold medicine. The chemical structure of cloperastine is quite similar to that of the antihistamine drug diphenhydramine, which is reported to inhibit hERG K+ channels and clinically induce long QT syndrome after overdose. To analyze its proarrhythmic potential, we compared effects of cloperas- tine and diphenhydramine on the hERG K+ channels expressed in HEK293 cells. We further as- sessed their effects on the halothane-anesthetized guinea-pig heart under the monitoring of mono- phasic action potential (MAP) of the ventricle. Cloperastine inhibited the hERG K+ currents in a concentration-dependent manner with an IC50 value of 0.027 μM, whose potency was 100 times greater than that of diphenhydramine (IC50; 2.7 μM). In the anesthetized guinea pigs, cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT intervalPROOF and MAP duration without affecting PR interval or QRS width. Diphenhydramine at a therapeutic dose of 10 mg/kg prolonged the QT interval and MAP duration together with increase in PR interval and QRS width. The present re- sults suggest that cloperastine may be categorized as a QT-prolonging drug that possibly induces arrhythmia at overdoses like diphenhydramine does.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Japanese Pharmacopoeial Forum
    Japanese Pharmacopoeial Forum Vol. 27 No. 1 March 2018 Contents Revision Drafts Tipepidine Hibenzate Tablets ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 178 Drafts for JP 18 Ursodeoxycholic Acid ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 179 １. General Notices ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 138 ４. Official Monographs－Crude Drugs ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 179 Revision Drafts for Second Supplement to JP 17 (1) Addition ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 179 １. General Rules for Preparations Goshuyuto Extract ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 179 [3] Monographs for Preparations ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 138 (2) Revision ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 181 ２. General Tests, Processes and Apparatus Bitter Tincture ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 181 (1) Addition Bofutsushosan Extract ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 182 2.66 Elemental Impurities－Procedures ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 139 Calumba ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 182 (2) Revision Powdered Calumba ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 182 9.41 Reagents, Test Solutions ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 142 Hochuekkito Extract ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 182 ３. Official Monographs Japanese Angelica Rootꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 183 (1) Addition Powdered Japanese Angelica Root ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 183 Bromfenac Sodium Hydrate ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 143 Juzentaihoto Extract ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 183 Bromfenac Sodium Ophthalmic Solution Kakkontokasenkyushin'i Extract ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 184 ꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏꞏ 144 Kamikihito
    [Show full text]
  • Identification of Novel Small Molecule Inhibitors for Solute Carrier SGLT1
    Burggraaf et al. J Cheminform (2019) 11:15 https://doi.org/10.1186/s13321-019-0337-8 Journal of Cheminformatics RESEARCH Open Access Identifcation of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling Lindsey Burggraaf1, Paul Oranje2, Robin Gouka2, Pieter van der Pijl2, Marian Geldof2, Herman W. T. van Vlijmen1,3, Adriaan P. IJzerman1 and Gerard J. P. van Westen1* Abstract Sodium-dependent glucose co-transporter 1 (SGLT1) is a solute carrier responsible for active glucose absorption. SGLT1 is present in both the renal tubules and small intestine. In contrast, the closely related sodium-dependent glucose co-transporter 2 (SGLT2), a protein that is targeted in the treatment of diabetes type II, is only expressed in the renal tubules. Although dual inhibitors for both SGLT1 and SGLT2 have been developed, no drugs on the market are targeted at decreasing dietary glucose uptake by SGLT1 in the gastrointestinal tract. Here we aim at identifying SGLT1 inhibitors in silico by applying a machine learning approach that does not require structural information, which is absent for SGLT1. We applied proteochemometrics by implementation of compound- and protein-based information into random forest models. We obtained a predictive model with a sensitivity of 0.64 0.06, specifcity of 0.93 0.01, positive predictive value of 0.47 0.07, negative predictive value of 0.96 0.01, and Matthews± correlation coefcient± of 0.49 0.05. Subsequent to model± training, we applied our model in virtual± screening to identify novel SGLT1 inhibi- tors. Of± the 77 tested compounds, 30 were experimentally confrmed for SGLT1-inhibiting activity in vitro, leading to a hit rate of 39% with activities in the low micromolar range.
    [Show full text]
  • Novel Natural and Synthetic Inhibitors of Solute Carriers SGLT1 and SGLT2
    Received: 21 March 2019 | Revised: 5 June 2019 | Accepted: 6 June 2019 DOI: 10.1002/prp2.504 ORIGINAL ARTICLE Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2 Paul Oranje1 | Robin Gouka1 | Lindsey Burggraaff2 | Mario Vermeer1 | Clément Chalet1 | Guus Duchateau1 | Pieter van der Pijl1 | Marian Geldof1 | Niels de Roo1 | Fenja Clauwaert3 | Toon Vanpaeschen3 | Johan Nicolaï3 | Tom de Bruyn3 | Pieter Annaert3 | Adriaan P. IJzerman2 | Gerard J. P. van Westen2 1Unilever Research & Development, Vlaardingen, The Netherlands Abstract 2Division of Drug Discovery & Safety, Leiden Selective analogs of the natural glycoside phloridzin are marketed drugs that re‐ Academic Centre for Drug Research, Leiden duce hyperglycemia in diabetes by inhibiting the active sodium glucose cotrans‐ University, Leiden, The Netherlands 3Drug Delivery and Disposition, Department porter SGLT2 in the kidneys. In addition, intestinal SGLT1 is now recognized as a of Pharmaceutical and Pharmacological target for glycemic control. To expand available type 2 diabetes remedies, we Sciences, KU Leuven, Leuven, Belgium aimed to find novel SGLT1 inhibitors beyond the chemical space of glycosides. We Correspondence screened a bioactive compound library for SGLT1 inhibitors and tested primary hits Gerard J. P. van Westen, Division of Drug Discovery & Safety, Leiden Academic Centre and additional structurally similar molecules on SGLT1 and SGLT2 (SGLT1/2). Novel for Drug Research, Leiden University, SGLT1/2 inhibitors were discovered in separate chemical clusters
    [Show full text]
  • Supporting Information
    Supporting Information Su et al. 10.1073/pnas.1602815113 SI Methods then a thrombin protease recognition sequence to the N terminus Constructs. DNA fragments encoding different constructs were of cloned genes. amplified by PCR using Phusion DNA polymerase (New England hSlo1 was cloned into RML6 vector and was expressed in Biolabs) and cloned into expression vectors modified by the CHO cells. MacKinnon laboratory for yeast, insect, and mammalian cells. All mTRAAK chimeric construct used in protein purification was constructs were confirmed by sequencing (Genewiz). cloned into RML6 vector and was expressed in CHO cells. Human ROMK truncation mutant (residues 35–367), mouse Constructs for Protein Purification. Mouse GIRK2 (mGIRK2) Kir2.1 truncation mutant (residues 41–368), and human Kir7.1 truncation mutant (residues 52–380) was cloned into RML1 vector truncation mutant (residues 13–360) were cloned into RML6 and was expressed in Pichia pastoris strain SMD1163 (Invitrogen). vector and were expressed in HEK293 cells. RML1 vector is modified from pPICZ (Invitrogen) by adding Mouse THIK1, mouse TRESK, rat TWIK2, mouse TALK1, a PreScission protease recognition sequence (LEVLFQ/GP) and mouse TASK3 genes were cloned into RML6 vector and were followed by an EGFP sequence and then a 1D4 tag sequence expressed in CHO cells. (TETSQVAPA) to the C terminus of cloned genes. Human Gβ1 and Gγ2 were individually cloned into pFastbac Protein Purification. vector (Invitrogen), and the Gβγ complex was expressed in High mGIRK2 purification. The cloned 1D4-tagged mGIRK2 construct was Five insect cells (Invitrogen) by virus coinfection. linearized with Pme1 and transformed into Pichia cells by elec- Mouse TRAAK (mTRAAK) truncation mutant (residues 1–275 troporation (Bio-Rad).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY DATA Supplementary Table 1. Case listing of bladder cancer related to pioglitazone therapy CASE Event From Age Gender Therapy Concomitant Co-morbidity year clinical duration Drugs study (days) 4172635 2004 No 88 M n.a. gliclazide acarbose ezetimibe metformin ramipril atorvastatin 4125536 2004 Yes 73 M 337 lansoprazole 5653392 2004 Yes 53 M n.a. isepamicin bezafibrate famotidine ketoprofen ofloxacin sildenafil sulpiride valsartan ethyl icosapentate 5731398 2004 Yes 75 M n.a. dextromethorphan tranexamic acid telmisartan salicylamide promethazine glimepiride metformin cloperastine amoxicillin cefdinir carbocisteine paracetamol caffeine 6462605 2005 No 67 M n.a. methotrexate psoriatic tamsulosin arthropathy sitagliptin simvastatin ©2011 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-2412/-/DC1 SUPPLEMENTARY DATA CASE Event From Age Gender Therapy Concomitant Co-morbidity year clinical duration Drugs study (days) ramipril metformin infliximab folic acid escitalopram ranitidine 5960713 2005 No 54 M 63 lisinopril simvastatin gemfibrozil clopidogrel 5996136 2005 Yes 69 M 418 atenolol acetylsalicylic acid 6280536 2006 No 56 F n.a. oxybutynin multiple interferon beta-1a sclerosis 6209285 2006 No 81 F n.a. atorvastatin celecoxib fluticasone gabapentin levothyroxine sodium lisinopril metformin multivitamins risedronic acid salbutamol salmeterol 6144746 2006 No 62 F n.a. salmeterol ipratropium bromide lisinopril potassium insulin glargine vitamins duloxetine ©2011 American
    [Show full text]